

1 Endogenous Retroelement Expression in the Gut Microenvironment of People Living with HIV-

2 1

3

4 Nicholas Dopkins\*<sup>1</sup>, Tongyi Fei<sup>1</sup>, Stephanie Michael<sup>1</sup>, Nicholas Liotta<sup>1</sup>, Kejun Guo<sup>2,3,4</sup>, Kaylee

5 L. Mickens<sup>2,3,4</sup>, Brad S. Barrett<sup>2,3,4</sup>, Matthew L. Bendall<sup>1</sup>, Stephanie M. Dillon<sup>2,3,4</sup>, Cara C.

6 Wilson<sup>2,3,4</sup>, Mario L. Santiago<sup>2,3,4</sup> and Douglas F. Nixon<sup>1</sup>

7

8 Keywords: human endogenous retrovirus (HERV), interferons, human immunodeficiency virus

9 type I (HIV-I), Endogenous Retroelement (ERE), Long interspersed nuclear element (LINE)

10

11 <sup>1</sup>Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York,

12 NY, United States of America.

13 <sup>2</sup>Department of Medicine, University of Colorado School of Medicine, Aurora, CO, United

14 States of America.

15 <sup>3</sup>RNA Bioscience Initiative, University of Colorado School of Medicine, Aurora, CO, United

16 States of America.

17 <sup>4</sup>Department of Immunology and Microbiology, University of Colorado School of Medicine,

18 Aurora, CO, United States of America.

19

20 **Correspondence:**

21 Nicholas Dopkins, PhD

22 Email: [nid4009@med.cornell.edu](mailto:nid4009@med.cornell.edu)

23

## 24 **Summary**

25

26 **Background:** Endogenous retroelements (EREs), including human endogenous retroviruses  
27 (HERVs) and long interspersed nuclear elements (LINEs), comprise almost half of the human  
28 genome. HIV-1 infects a target cell already possessing ancient retroviral genetic material, and  
29 exogenous HIV-1 infection modulates the expression of cell associated EREs. Following initial  
30 HIV-1 infection, there is a rapid destruction of CD4+ cells in the gut associated lymphoid tissue  
31 (GALT). Our previous studies of the interferome in the gut suggest potential mechanisms  
32 regarding how IFN $\beta$  may drive HIV-1 gut pathogenesis. As ERE activity is suggested to partake  
33 in type 1 immune responses and is incredibly sensitive to viral infections, we sought to elucidate  
34 underlying interactions between ERE expression and GALT dynamics in PLWH.

35

36 **Methods:** ERE expression profiles from bulk RNA sequencing of colon biopsies and PBMC  
37 were compared between a cohort of PLWH prior to or within 7 days of initiating antiretroviral  
38 therapy (ART) (n=19) and uninfected controls (n=13). Individual EREs were then compared  
39 with the profiling of uninfected gut CD4+ T cells activated with type 1 interferons (IFN-Is) (n=3)  
40 to elucidate potential mechanisms for their induction in PLWH.

41

42 **Findings:** 59 EREs were differentially expressed in the colon of PLWH when compared to  
43 uninfected controls (Wald's Test with Benjamin-Hochberg correction:  $p_{adj} < 0.05$  and  $FC \leq -1$   
44 or  $\geq 1$ ). Of these 59, 12 EREs were downregulated in PLWH and 47 were upregulated. Colonic  
45 expression of the ERE loci LTR19\_12p13.31 and L1FLnI\_1q23.1s showed significant  
46 correlations with CD8+ T Cells and dendritic cell subset frequencies in the GI tract (Spearman's

47 Correlation:  $p$  value  $< 0.05$ ). Furthermore L1FLnI\_1q23.1s showed a significant upregulation in  
48 the blood of PLWH when compared to uninfected controls (T test:  $p < 0.05$ ) suggesting a  
49 common mechanism of differential ERE expression in PBMC and GALT.

50

51 **Interpretation:** ERE activity has been largely understudied in genomic characterizations of  
52 human pathologies. We show that the activity of certain EREs in the GI tract of PLWH is  
53 deregulated, supporting our hypotheses that their underlying activity could function as  
54 (bio)markers and potential mediators of pathogenesis in HIV-1 reservoirs.

55

56 **Funding:** NCI CA260691 (DFN) and NIAID UM1AI164559 (DFN).

57

58

59

60

61

62

63

64

65

66

67

68

69

## 70 **Introduction**

71 Human immunodeficiency virus type I (HIV-1) is a retrovirus that infects immune cells  
72 by binding to receptors on the cell surface<sup>1</sup>. HIV-1 infects host cells by integrating a copy of the  
73 viral genome into the host genome, resulting in proviruses that then hijack the host cell's  
74 replicative machinery to produce the building blocks of infectious particles<sup>1</sup>. The HIV-1 lifecycle  
75 may rapidly deplete host CD4+ T cell populations and disrupt global immune dynamics<sup>2</sup>.  
76 Disruptions to the host immune system predispose people living with HIV-1 (PLWH) to life-  
77 threatening comorbidities<sup>3</sup>. Since 1996, life expectancy and quality of life for PLWH have risen  
78 due to the advent of antiretroviral therapies (ARTs) that pharmacologically inhibit key processes  
79 of the retroviral life cycle<sup>4</sup>. Unfortunately, ART merely suppresses retroviral processes,  
80 emphasizing the need for cure strategies that rid individuals of latent proviral reservoirs which  
81 may resume infectious particle formation after a lapse in treatment<sup>5,6</sup>. One such reservoir site is  
82 the gastrointestinal (GI) associated lymphoid tissue (GALT)<sup>7,8</sup>, which is particularly rich in  
83 CD4+ T cells<sup>9</sup>. HIV-1 induced immunopathologies in the GALT are associated with severe  
84 comorbidities in PLWH<sup>10,11</sup>. Many of these pathologies could be sustained by the accumulation  
85 of plasmacytoid dendritic cells (pDCs) that are trafficked to the GI tract during chronic HIV-1  
86 infection<sup>12</sup>. Models of Simian Immunodeficiency Virus (SIV), a retrovirus closely related to  
87 HIV-1, demonstrate that pDCs traffic from the circulation, where they are depleted, to the GALT,  
88 where their overabundance contributes to immunopathologies that allow the site to become the  
89 primary source of viral replication<sup>13,14</sup>. pDCs reflect a unique subset of DCs whose primary  
90 function is not antigen presentation but is instead immunomodulation through the release of  
91 cytokines<sup>15</sup>. In the acute stages of HIV-1 infection, pDCs produce type 1 interferons (IFN-Is) as  
92 one of the first lines of defense against the virus<sup>16</sup>, and are therefore protective. However, the

93 sustainment of their IFN-I production during the chronic stages of infection exhausts and  
94 deregulates antiviral immunity, negatively impacting the health of PLWH<sup>12,16-18</sup> .

95       To better characterize how immunopathologies in PLWH develop, we investigated how  
96 endogenous retroelement (ERE) expression may underlie the development of HIV-1 induced  
97 immune deregulation. EREs are highly abundant sequences estimated to make up roughly ~40%  
98 of the human genome<sup>19</sup>. In humans, EREs include long interspersed nuclear elements (LINEs),  
99 short interspersed nuclear elements (SINEs), and human endogenous retroviruses (HERVs)<sup>20</sup>.  
100 Previous studies have demonstrated that ERE activity is highly susceptible to change during  
101 infection with HIV-1<sup>21-31</sup>. While IFN-I signaling may activate EREs proximal to interferon  
102 stimulated genes (ISGs), other EREs, such as HERV elements, can be directly trans-activated by  
103 HIV-1 cofactors due to high sequence homology between endogenous and exogenous  
104 retroviruses<sup>21,22,24,32,33</sup>. This homology can be so substantial that certain HERV-K18 and HERV-  
105 W products can be incorporated in the assembly of HIV-1 particles<sup>34-38</sup>. ERE activity also  
106 functions as a major regulator of transcriptional networks that have been co-opted in organismal  
107 physiology<sup>39,40</sup>. In immunity, examples of ERE activity cooption suggest their intimate  
108 association with the host mounted responses<sup>41,42</sup>. Recurrent observations continually reinforce  
109 hypotheses that EREs likely participate in human health and disease through poorly understood  
110 mechanisms<sup>42-46</sup>. The activity of multiple HERVs<sup>21-28</sup> and LINEs<sup>29,30</sup> is altered during HIV-1  
111 infection, which then impacts host gene expression<sup>24</sup>, packaging of HIV-1 particles<sup>34-38</sup>, and  
112 immunity<sup>25,47</sup>. For the purpose of further defining HIV-1 mediated gut pathogenesis, we sought  
113 to characterize how ERE activity at the RNA level is modulated in the gut microenvironment of  
114 PLWH. Since EREs have been largely overlooked in genomic approaches to classify underlying

115 components of human pathologies, we hypothesize that their consideration would identify novel  
116 markers of HIV-1 pathogenesis in the gut.

117 ERE expression at the RNA level was quantified in colon biopsies collected from a  
118 cohort of viremic individuals prior to or at the initiation of ART<sup>17</sup> to identify those best  
119 correlating with viral load. We next overlaid these findings with IFN-I stimulated gut CD4+ T  
120 cells to estimate if the differential expression of EREs in the gut of PLWH is driven by the HIV-1  
121 lifecycle or by innate immunopathologies. Collectively, our analyses demonstrate that a subset of  
122 ERE loci are impacted in PLWH. The bulk of PLWH-upregulated EREs in the gut are not  
123 upregulated by IFN-I stimulation of gut CD4+ T cells, suggesting their activation by other  
124 aspects of the HIV-1 life cycle or the host response. Two identified EREs, LTR19\_12p13.31 and  
125 L1FLnI\_1q23.1s, further correlated with myeloid and lymphoid immune cell abundances.  
126 Collectively, incorporation of the GI-specific expression of LTR19\_12p13.31 and  
127 L1FLnI\_1q23.1s can better define HIV-1 driven immunopathologies of the GALT, and the  
128 expression of these elements may possess underlying roles in pathogenesis.

129

## 130 **Methods**

### 131 *Locus-specific quantification of ERE expression at the RNA level*

132 RNA sequencing FASTQ files of colon pinch biopsies and interferome arrays of  
133 uninfected CD4+ T cells were obtained from a previously published study<sup>17</sup> under the Bioproject  
134 accession numbers “PRJNA558500” and “PRJNA558974”, respectively. RNA sequencing  
135 FASTQ files performed on the PBMC fraction from the same participants are available under the  
136 Bioproject accession number “PRJNA659373”. FASTQ files were aligned to the human genome  
137 build 38 (hg38) using STAR (v2.7.9.a)<sup>48</sup>. STAR alignment was performed using the parameters

138 “--outSAMstrandField intronMotif --outFilterMultimapNmax 200 --winAnchorMultimapNmax  
139 200” for the purpose of capturing multimapping ERE reads. We then used Telescope (v1.0.3)<sup>49</sup>,  
140 which utilizes an expectation-maximization algorithm to improve upon the definition of  
141 ubiquitously mapping ERE transcripts to a custom annotation, for locus-specific approximation  
142 of ERE expression. The Telescope assign module was performed using the parameters “--  
143 theta\_prior 200000 -- max\_iter 1000” to align reads to a custom annotation of EREs accessible at  
144 [https://github.com/mlbendall/telescope\\_annotation\\_db](https://github.com/mlbendall/telescope_annotation_db). Metadata for the ERE annotation  
145 predicting the intronic, exonic, and intergenic status of individual loci in the Telescope  
146 annotation relative to coding gene annotations can be found at  
147 [https://github.com/liniguez/Telescope\\_MetaAnnotations](https://github.com/liniguez/Telescope_MetaAnnotations). Original code produced for analysis  
148 can be accessed at <https://github.com/NicholasDopkins/JuneHIVMucosa>.

149

### 150 *Differential expression analysis*

151 Lowly abundant EREs were filtered from downstream analysis by ensuring that all EREs  
152 possessed at least 2 reads within 10% of the total samples. Differential expression analysis was  
153 performed between the ERE expression profiles of uninfected control and PLWH colon biopsies  
154 using standard DESEQ2 (v1.30.1)<sup>50</sup> parameters. Differential expression analysis was performed  
155 between the ERE expression profiles of IFN-I stimulated gut CD4+ T cells using DESEQ2 with  
156 the parameters “parallel = T” and “betaPrior = T”. Results were extracted as DESEQ objects,  
157 with a numbered contrast of each group compared against all others. Differentially expressed  
158 EREs were visualized with the packages pheatmap (v1.0.12), ggVennDiagram (v1.2.2)<sup>51</sup> and  
159 EnhancedVolcano (v1.8.0). Individual EREs were visualized with a custom function that  
160 overlays geom\_jitter and geom\_boxplot functions provided by ggplot2 v(3.3.5)<sup>52</sup> to produce a

161 Tukey box and whisker plot that displays individual replicates. Clinical parameters of  
162 immunopathologies were provided by previously published metadata<sup>17,18,53,54</sup> and a table  
163 summary is available at  
164 <https://github.com/NicholasDopkins/JuneHIVMucosa/blob/main/Metadata.csv>. Principal  
165 coordinate analyses (PCA) were performed on variance stabilizing transformed DESEQ outputs  
166 in order to visualize if untested confounding factors explained observations pertaining to  
167 differential expression analyses. PCA generation was performed using PCAtools (v2.2.0) with  
168 the variable parameter set to “removeVar = 0.1”.

169

#### 170 *Integrative Genomics Viewer*

171 National Center for Biotechnology Information (NCBI) Reference Sequence Database  
172 (Refseq)<sup>55</sup>, ENCyclopedia Of DNA Elements<sup>56</sup> (Gencode), and Telescope<sup>49</sup> annotations of the  
173 human genome were loaded into Integrative Genomics Viewer<sup>57</sup> (IGV) for alignment of  
174 StringTie<sup>58</sup> reconstructed transcriptomes from uninfected controls and PLWH samples.

175

#### 176 *Statistics*

177 Standard DESEQ2 statistics of Wald’s Test with Benjamin-Hochberg correction of p  
178 values were utilized for the identification of significantly deregulated EREs between uninfected  
179 controls and PLWH samples. EREs a log2 fold change of >1 or <-1 and an adjusted p value  
180 (padj) of <0.05 were deemed significantly differentially expressed. Statistical values for  
181 correlations between clinical parameters and ERE expression were conducted using Pearson’s  
182 correlation coefficient values provided by ggplot2. To elucidate values of significance regarding  
183 of ERE expression between experimental groups, T tests were used to gather significance values



184 when stated. For significance of post hoc tests the following scale is used to indicate p values  
185 when applicable: ns,  $p > 0.05$ ; \*,  $p < 0.05$ ; \*\*,  $p < 0.01$ ; \*\*\*,  $p < 0.005$

186

### 187 *Clinical cohort*

188 ERE expression analyses were conducted using FASTQ files from previously generated RNAseq  
189 data collected from colonic tissue and PBMC fractions collected from 19 PLWH and 13 age- and  
190 sex-matched controls, and associations with features of HIV-1 pathogenesis were determined  
191 using archived datasets of colon and systemic immunological and virological parameters<sup>17,18,53,54</sup>.  
192 On average, PLWH had been infected with HIV-1 (defined by the first HIV-1 seropositive test)  
193 for  $5.25 \pm 1.1$  (mean  $\pm$  SEM) years. PLWH were ART-naive or were not on ART for more than 7  
194 days in the preceding 6 months, and had CD4 T cell counts  $>200$  cells/ $\mu$ l within 3 months of  
195 clinical visit. Exclusion criteria for both cohorts are extensively detailed elsewhere<sup>53</sup>. In addition  
196 to blood samples, study participants underwent a flexible sigmoidoscopy with multiple colon  
197 pinch biopsies obtained. Clinical characteristics for the study participants included in this current  
198 study are detailed in Supplemental Table 1.

199

### 200 *Immune system characterization of PLWH and uninfected controls*

201 Methods used to generate the archived datasets have been extensively detailed<sup>17,18,53,54,59,60</sup>. In  
202 brief, indicators of systemic inflammation were assessed with plasma IL-6 concentrations by  
203 ELISA, and microbial translocation was measured by plasma LPS concentrations with the  
204 Limulus Amebocyte Lysate assay<sup>53</sup>. Frequencies of colon mDCs, pDCs, and T cells were  
205 determined using multi-color flow cytometry<sup>53,54</sup> and expressed as an absolute number per gram  
206 of tissue based on the frequency within viable CD45+ cells, initial cell counts, and biopsy

207 weights. Colon tissue HIV-1 RNA was quantified by real-time PCR and HIV-1 RNA copy  
208 numbers normalized per CD4 T cell within each biopsy calculated by the percent of all viable  
209 cells that were CD45+CD3+CD4+ as determined by flow cytometry and weight of each biopsy  
210 and reported as HIV-1 RNA per million CD4 T cell<sup>53</sup>.

211

### 212 *Ethics Statement*

213 Analyses performed in this study were performed on deidentified and publicly available or  
214 previously archived data. The original clinical study was approved by the Colorado Multiple  
215 Institutional Review Board and all study participants voluntarily gave written, informed  
216 consent<sup>17,18,53,54</sup>.

217

### 218 *Role of Funders*

219 The funding bodies had no influence on the planning, conduction and analysis of data  
220 performed during this study.

221

## 222 **Results**

### 223 *HIV-1 status influences endogenous retroelement expression in the gut microenvironment*

224 Following preprocessing to remove lowly abundant transcripts, we quantified the  
225 expression of 13,706 EREs in colon pinch biopsies collected from PLWH in comparison to age  
226 and sex-matched HIV-1-uninfected controls (Fig. 1a). Significance in differential expression  
227 between controls and PLWH was found for 59 ERE loci (Fig. 1b and Fig. 1c). Of these 59 loci,  
228 47 were upregulated and 12 were downregulated in PLWH. All HERVs differentially expressed  
229 were upregulated in PLWH when compared to controls. Overall, ERE activity at the RNA level

230 displays discrete changes in the gut microenvironment in viremic individuals prior to the  
231 initiation of ART. Further consideration of the phylogenies and chromosomal origin of ERE  
232 expression profiles demonstrated no distinctive alterations in PLWH when compared to controls,  
233 suggesting no large-scale changes in ERE expression in the gut microenvironment of PLWH  
234 (Fig. S1). To infer mechanisms by which HIV-1 infection induces the differential expression of  
235 EREs in the gut, we next quantified changes in expression resulting from IFN-I stimulation of  
236 uninfected gut-derived CD4+ T cells. IFN-Is do not shift the global landscape of ERE activity at  
237 the RNA level (Fig. S2). Discrete changes in locus-specific expression demonstrate that IFN-I  
238 activation of uninfected gut CD4+ T cells share upregulated expression of 23 EREs, suggesting  
239 that they are IFN-inducible (Fig. S3 and Fig. S4). 7 of these 23 EREs were upregulated in the gut  
240 of PLWH, suggesting immune-dependent mechanisms for their in HIV-1 infection, while 35 of  
241 the 42 upregulated EREs in PLWH showed no significant induction by IFN-I stimulation (Fig.  
242 S5). Collectively, HIV-1 infection upregulates specific EREs in the gut of PLWH through both  
243 IFN-dependent and IFN-independent mechanisms.

244

245 *Correlation between gut endogenous retroelement expression and viral load in people living*  
246 *with HIV-1*

247 Pearson's correlation coefficients were calculated for all differentially expressed EREs in  
248 the gut of PLWH to identify any potential links with their expression and HIV-1 infection  
249 severity as determined by circulating HIV-1 viral load. Of the 59 differentially expressed EREs,  
250 three showed near significant ( $p < 0.10$ ) positive correlations between colonic expression and viral  
251 load in PLWH. L1FLnI\_1q23.1s possessed a positive association with viral load in the  
252 circulation (Fig. 2a) and is upregulated in the colon of PLWH when compared to uninfected

253 controls (Fig. 2b). In PBMCs collected from the same participants, expression of  
254 L1FLnI\_1q23.1s is significantly upregulated in concurrence with gut expression of the element  
255 (Fig. 2c). Analysis of IFN-I activated gut CD4+ T cells suggests that IFN alpha 1 (IFNa1) and  
256 IFN beta (IFNb) may contribute to the upregulated expression of L1FLnI\_1q23.1s, however no  
257 IFN-Is yielded significant effects (Fig. 2d). IGV demonstrates that the L1FLnI\_1q23.1s locus is  
258 an ERE within the Pyrin And HIN Domain Family Member 1 (PYHIN1) gene with minor  
259 differences in the putative alignments provided by StringTie for uninfected controls and PLWH  
260 samples (Fig. 2e). L1FLnI\_5q32o possessed a positive association with viral load in the  
261 circulation (Fig. 2f) and is upregulated in the colon of PLWH when compared to controls (Fig.  
262 2g). In PBMCs collected from the same study participants, expression of L1FLnI\_5q32o is  
263 significantly upregulated in concurrence with gut expression of the element (Fig. 2h). Analysis  
264 of IFN-I activated gut CD4+ T cells suggests that IFN-Is yield no significant effects on the  
265 expression of L1FLnI\_5q32o (Fig. 2i). IGV demonstrates that the L1FLnI\_5q32o locus is an  
266 ERE within the Janus Kinase And Microtubule Interacting Protein 2 (JAKMIP2) gene with no  
267 differences in the putative alignments provided by StringTie for PLWH and control samples  
268 (Fig. 2j). LTR19\_12p13.31 possessed a positive association with viral load in the circulation  
269 (Fig. 2k) and is upregulated in the colon of PLWH when compared to controls (Fig. 2l). In  
270 PBMCs collected from the same study participants, expression of LTR19\_12p13.31 shows a  
271 non-significant upregulation (Fig. 2m). Analysis of IFN-I activated gut CD4+ T cells suggests  
272 that IFN-Is yield no significant effects on the expression of LTR19\_12p13.31 (Fig. 2n). IGV  
273 demonstrates that LTR19\_12p13.31 locus is an ERE that overlaps the Pregnancy Zone Protein  
274 (PZP) and Killer Cell Lectin Like Receptor G1 (KLRG1) genes with a unique transcript in the  
275 putative alignments of PLWH samples provided by StringTie (Fig. 2o). Collectively, expression

276 of the EREs L1FLnI\_1q23.1s, L1FLnI\_5q32o, and LTR19\_12p13.31 show associations with  
277 blood HIV-1 RNA levels,, and their induction in the gut may likely be independent of IFN-I  
278 mediated pathologies.

279  
280 *Correlation Between LTR19\_12p13.31 and L1FLnI\_1q23.1s expression and immune signatures*  
281 *of the gut microenvironment in people living with HIV-1*

282 We next analyzed how expression of L1FLnI\_1q23.1s, L1FLnI\_5q32o and  
283 LTR19\_12p13.31 correlate with cellular abundances that may be associated with pathogenesis in  
284 the gut of PLWH. There were no significant associations between the number colon CD4+ T  
285 cells (measured per gram of gut tissue)with LTR19\_12p13.31 (Fig. 3a) and L1FLnI\_1q23.1s  
286 expression (Fig. 3b). LTR19\_12p13.31 demonstrated significant positive correlations with the  
287 number of colon CD8+ T cells (Fig. 3c) and IFN gamma (IFN $\gamma$ )+CD8+ T cells (Fig. 3e),  
288 whereas L1FLnI\_1q23.1s demonstrated near significant positive correlations with CD8+ (Fig.  
289 3d) and IFN $\gamma$ +CD8+ T cell (Fig. 3f) abundances. Further consideration into dendritic cell (DC)  
290 abundances demonstrate that LTR19\_12p13.31 (Fig. 3g) and L1FLnI\_1q23.1s (Fig. 3h) show  
291 near significant positive correlations with CD11c+ myeloid DCs (mDCs), while  
292 LTR19\_12p13.31 (Fig. 3i) displayed a significant positive correlation and L1FLnI\_1q23.1s (Fig.  
293 3j) displayed a near significant positive association with plasmacytoid DCs (pDCs). Amongst  
294 mDCs, LTR19\_12p13.31 (Fig. 3k) and L1FLnI\_1q23.1s (Fig. 3l) show significant positive  
295 correlations with the CD1c- mDCs, but not with CD1c+ mDCs (Fig. S6), suggesting potential  
296 perturbations related to specific mDC subsets<sup>54</sup>. Expression of the ERE L1FLnI\_5q32o did not  
297 demonstrate positive or negative correlations with CD4+ T cells, CD8+ T cells, IFN $\gamma$ +CD8+ T  
298 cells, CD11c+ mDCs, pDCs, or CD1c- mDCs in PLWH (Fig. S7). In analyses of frequencies of

299 CD4 T helper (Th) cell subsets, L1FLnI\_1q23.1s significantly positively correlated with  
300 IL22+IFN $\gamma$ -IL17- CD4+ T cells (i.e. Th22) and IFN $\gamma$ -IL17+ CD4+ T cells (i.e Th17), and  
301 trended towards a significant positive association with IFN $\gamma$ +IL17+ CD4+ T cells (i.e.  
302 inflammatory Th17 cells) (Fig. S8). L1FLnI\_5q32o (Fig. S9) and LTR19\_12p13.31 (Fig. S10)  
303 demonstrated no significant correlations with analyzed CD4+ T cell subset abundances in the  
304 gut. Furthermore, systemic markers of microbial translocation and inflammation including as  
305 plasma lipopolysaccharide (LPS) and interleukin (IL)-6, were analyzed and demonstrated  
306 insignificant associations with LTR19\_12p13.31, L1FLnI\_1q23.1s, or L1FLnI\_5q32o expression  
307 (Fig. S11). Collectively, LTR19\_12p13.31 and L1FLnI\_1q23.1s, but not L1FLnI\_5q32o, show  
308 significant associations with the various innate and adaptive immune cell frequencies in the gut  
309 of PLWH.

310

## 311 **Discussion**

312 In this study, we leverage modulations in ERE activity at the RNA level in the GI tract of  
313 untreated PLWH with frequencies of immune cell populations that are likely critical players in  
314 driving HIV-1 gut pathogenesis<sup>11</sup>. As the derepression of EREs may possess immunomodulatory  
315 roles in human diseases<sup>42,61</sup>, our results suggest further investigation into their activity in HIV-1  
316 pathogenesis. By analysis of RNA sequencing from colon biopsies of uninfected controls vs  
317 untreated PLWH, we identified 59 differentially expressed EREs associated with HIV. By  
318 finding correlations between their colonic expression and circulating viral load, we were able to  
319 narrow further investigations to focus on 3 EREs upregulated in PLWH that might indicate the  
320 severity of HIV-1 pathogenesis in the gut, or function as markers of immune deregulation. The  
321 EREs LTR19\_12p13.31 and L1FLnI\_1q23.1s best correlated with cellular abundances including

322 higher frequencies of pDCs, CTLs, and CD1c- mDCs. L1FLnI\_5q32o demonstrated no  
323 associations with these cellular markers, however, did show associations with differential  
324 abundances of CD4+ T cell Th subsets that were not found with LTR19\_12p13.31 and  
325 L1FLnI\_1q23.1s expression. By considering their expression in PBMCs from the same study  
326 participants, we observed a significant upregulation in L1FLnI\_1q23.1s expression and a non-  
327 significant upregulation in LTR19\_12p13.31. In accordance with previous studies<sup>22</sup>, we observe  
328 significant alterations in ERE activity at the RNA level in the PBMC fraction of PLWH and  
329 uninfected controls (Fig. S12). This suggests future use of L1FLnI\_1q23.1s as a potential  
330 circulating biomarker for deregulations of immunity in the gut microenvironment of PLWH,  
331 while LTR19\_12p13.31 is more likely an intrinsic marker specific to the GI tract. Collectively,  
332 we find significant associations between LTR19\_12p13.31 and L1FLnI\_1q23.1s and cellular  
333 dynamics of the GALT in PLWH, further emphasizing their identity as biomarkers or potential  
334 mediators of immune deregulation.

335 Previous studies have demonstrated that ERE activity is widely changed in response to  
336 the HIV-1 lifecycle<sup>21,22,27,29,31</sup> and certain HIV-1 associated comorbidities<sup>62,63</sup>. ERE expression is  
337 also susceptible to changes in epigenetics and immunity that are elicited during viral  
338 infections and the host response<sup>64</sup>. While it remains unknown if the changes in expression for  
339 most EREs result from a bystander effect or by a cooption of host immunity in HIV-1 infection,  
340 their activity can be incorporated to better characterize poorly understood immunopathologies in  
341 viral infections. Here, we demonstrate that significant correlations can be established between  
342 differentially expressed EREs and cellular markers that likely contribute to GI  
343 immunopathologies of untreated HIV-1 infection. Some limitations of this study concern bulk  
344 RNA sequencing approaches utilized, leaving the data unable to discern what cell types are

345 responsible for the overexpression of differentially expressed EREs. As the cellular composition  
346 of the sequenced tissues fluctuates with disease severity, it is unclear whether the phenotype or  
347 mere abundance of disproportionate cell types, such as pDCs and CTLs, is responsible for their  
348 expression. Future studies that accurately quantify ERE expression from single cell RNA  
349 sequencing data that were not available from this cohort would provide further insight into the  
350 activation state of these EREs in the GI tract of PLWH. Additionally, due to the poorly defined  
351 molecular characteristics and low copy number of LTR19 HERV sequences, exceedingly little is  
352 known about their potential roles in health and disease. LTR19 sequences are a member of the  
353 HERVFA clade and are estimated to only possess roughly ~15 copies in the human genome<sup>65</sup>.

354 In conclusion, this study provides the first correlative link between ERE expression and  
355 the deregulations of GALT observed in untreated HIV-1 infection. While EREs can be  
356 modulated in context dependent manners by various aspects of HIV-1 infection, their potential  
357 roles in systemic immunity in the GI tract have remained undetermined. We also demonstrate  
358 that the IFN-I response mediates ERE expression in uninfected gut CD4+ T cells, however this  
359 only appears to be responsible for a distinct subset of roughly 7 differentially expressed  
360 elements. It is thus unclear if the HIV-1 lifecycle or IFN-I activity on CD4- cell types in the  
361 GALT are responsible for changes in ERE activity. We find that LTR19\_12p13.31 and  
362 L1FLnI\_1q23.1s are promising markers of HIV-1 pathogenesis in the gut and may possess  
363 undetermined roles in determining cellular composition. This study also provides one of the first  
364 observations of a differentially expressed LTR19 elements in a human disease, thus emphasizing  
365 the importance of their further study.

366

367 **Contributors**



368 ND co-designed the study, co-prepared the first manuscript draft, co-performed data analyses,  
369 co-curated code, led statistical analyses, and curated figures. TF co-prepared the first manuscript  
370 draft, co-performed data analyses, co-performed statistical analysis, co-curated code, and  
371 provided intellectual input critical to analysis. SM co-designed the study, co-prepared the first  
372 manuscript draft, co-performed data analyses, and provided intellectual input critical to data  
373 interpretation. NL co-performed analyses and co-curated code. KG provided intellectual input  
374 critical to hypothesis generation and co-provided data access. KLM provided intellectual input  
375 critical to hypothesis generation and co-provided data access. BSB provided intellectual input  
376 critical to hypothesis generation and co-provided data access. MLB provided intellectual input  
377 critical to hypothesis testing. SMD provided intellectual input critical to hypothesis generation  
378 and testing, co-provided data access, and performed immunological analysis of the gut  
379 microenvironment. CCW provided intellectual input critical to hypothesis generation and co-  
380 provided data access. DFN co-designed the study and co-prepared the first manuscript draft.  
381 MLS co-designed the study, co-prepared the first manuscript draft, and co-provided data access.  
382 All authors contributed to data interpretation, discussion regarding significances, and editing of  
383 the manuscript. All authors have read and approved the final manuscript.

384

### 385 **Declaration of Interests**

386 All authors have no potential conflicts of interests to disclose.

387

### 388 **Acknowledgments**

389 These works are supported by US NIH grants NCI CA260691 (DFN) and NIAID  
390 UM1AI164559 (DFN).

391

392 **Data Sharing Statement**

393 FASTQ from the bulk RNA sequencing reanalyzed by this study can be accessed at the  
394 NCBI sequence read archive (SRA) under PRJNA558974 and PRJNA558500. Code for analysis  
395 can be accessed at <https://github.com/NicholasDopkins/JuneHIVMucosa>. Details on running the  
396 Telescope pipeline can be accessed at <https://github.com/mlbendall/telescope>.

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414 **References**

- 415 1. Justiz Vaillant, A. A. & Gulick, P. G. HIV Disease Current Practice. in *StatPearls* (StatPearls  
416 Publishing, 2023).
- 417 2. Boasso, A., Shearer, G. M. & Chougnnet, C. Immune dysregulation in human  
418 immunodeficiency virus infection: know it, fix it, prevent it? *J. Intern. Med.* **265**, 78–96  
419 (2009).
- 420 3. Deeks, S. G., Overbaugh, J., Phillips, A. & Buchbinder, S. HIV infection. *Nat. Rev. Dis.*  
421 *Primer* **1**, 1–22 (2015).
- 422 4. Life expectancy of individuals on combination antiretroviral therapy in high-income  
423 countries: a collaborative analysis of 14 cohort studies. *Lancet* **372**, 293–299 (2008).
- 424 5. Sengupta, S. & Siliciano, R. F. Targeting the latent reservoir for HIV-1. *Immunity* **48**, 872–895  
425 (2018).
- 426 6. Veenhuis, R. T. *et al.* Monocyte-derived macrophages contain persistent latent HIV reservoirs.  
427 *Nat. Microbiol.* **8**, 833–844 (2023).
- 428 7. Thompson, C. G., Gay, C. L. & Kashuba, A. D. M. HIV Persistence in Gut-Associated  
429 Lymphoid Tissues: Pharmacological Challenges and Opportunities. *AIDS Res. Hum.*  
430 *Retroviruses* **33**, 513–523 (2017).
- 431 8. Kelley, C. F. *et al.* HIV-1 RNA Rectal Shedding Is Reduced in Men With Low Plasma HIV-1  
432 RNA Viral Loads and Is Not Enhanced by Sexually Transmitted Bacterial Infections of the  
433 Rectum. *J. Infect. Dis.* **204**, 761–767 (2011).
- 434 9. Mowat, A. McI. & Viney, J. L. The anatomical basis of intestinal immunity. *Immunol. Rev.*  
435 **156**, 145–166 (1997).

- 436 10. Guadalupe, M. *et al.* Severe CD4<sup>+</sup> T-Cell Depletion in Gut Lymphoid Tissue during  
437 Primary Human Immunodeficiency Virus Type 1 Infection and Substantial Delay in  
438 Restoration following Highly Active Antiretroviral Therapy. *J. Virol.* **77**, 11708–11717 (2003).
- 439 11. Dillon, S. M. & Wilson, C. C. Gut Innate Immunity and HIV Pathogenesis. *Curr.*  
440 *HIV/AIDS Rep.* **18**, 128–138 (2021).
- 441 12. Lehmann, C. *et al.* Longitudinal Analysis of Distribution and Function of Plasmacytoid  
442 Dendritic Cells in Peripheral Blood and Gut Mucosa of HIV Infected Patients. *J. Infect. Dis.*  
443 **209**, 940–949 (2014).
- 444 13. Ansari, A. A. *et al.* Blocking of  $\alpha 4\beta 7$  Gut-Homing Integrin during Acute Infection Leads  
445 to Decreased Plasma and Gastrointestinal Tissue Viral Loads in Simian Immunodeficiency  
446 Virus-Infected Rhesus Macaques. *J. Immunol.* **186**, 1044–1059 (2011).
- 447 14. Reeves, R. K. *et al.* SIV Infection Induces Accumulation of Plasmacytoid Dendritic Cells  
448 in the Gut Mucosa. *J. Infect. Dis.* **206**, 1462–1468 (2012).
- 449 15. Villadangos, J. A. & Young, L. Antigen-Presentation Properties of Plasmacytoid  
450 Dendritic Cells. *Immunity* **29**, 352–361 (2008).
- 451 16. O'Brien, M., Manches, O. & Bhardwaj, N. Plasmacytoid Dendritic Cells in HIV  
452 Infection. in *HIV Interactions with Dendritic Cells* (eds. Wu, L. & Schwartz, O.) vol. 762 71–  
453 107 (Springer New York, 2012).
- 454 17. Guo, K. *et al.* Qualitative Differences Between the IFN $\alpha$  subtypes and IFN $\beta$  Influence  
455 Chronic Mucosal HIV-1 Pathogenesis. *PLoS Pathog.* **16**, e1008986 (2020).
- 456 18. DILLON, S. M. *et al.* A Compartmentalized Type I Interferon Response in the Gut  
457 During Chronic HIV-1 Infection is Associated with Immunopathogenesis. *AIDS Lond. Engl.*  
458 **32**, 1599–1611 (2018).

- 459 19. Lander, E. S. *et al.* Initial sequencing and analysis of the human genome. *Nature* **409**,  
460 860–921 (2001).
- 461 20. Bourque, G. *et al.* Ten things you should know about transposable elements. *Genome*  
462 *Biol.* **19**, 199 (2018).
- 463 21. Bhardwaj, N., Maldarelli, F., Mellors, J. & Coffin, J. M. HIV-1 Infection Leads to  
464 Increased Transcription of Human Endogenous Retrovirus HERV-K (HML-2) Proviruses *In*  
465 *Vivo* but Not to Increased Virion Production. *J. Virol.* **88**, 11108–11120 (2014).
- 466 22. Contreras-Galindo, R., López, P., Vélez, R. & Yamamura, Y. HIV-1 infection increases  
467 the expression of human endogenous retroviruses type K (HERV-K) in vitro. *AIDS Res. Hum.*  
468 *Retroviruses* **23**, 116–122 (2007).
- 469 23. Vincendeau, M. *et al.* Modulation of human endogenous retrovirus (HERV) transcription  
470 during persistent and de novo HIV-1 infection. *Retrovirology* **12**, 27 (2015).
- 471 24. Srinivasachar Badarinarayan, S. *et al.* HIV-1 infection activates endogenous retroviral  
472 promoters regulating antiviral gene expression. *Nucleic Acids Res.* **48**, 10890–10908 (2020).
- 473 25. Jones, R. B. *et al.* HERV-K-specific T cells eliminate diverse HIV-1/2 and SIV primary  
474 isolates. *J. Clin. Invest.* **122**, 4473–4489 (2012).
- 475 26. Contreras-Galindo, R., Almodóvar-Camacho, S., González-Ramírez, S., Lorenzo, E. &  
476 Yamamura, Y. *Short Communication: Comparative Longitudinal Studies of HERV-K and*  
477 *HIV-1 RNA Titers in HIV-1-Infected Patients Receiving Successful versus Unsuccessful*  
478 *Highly Active Antiretroviral Therapy.* *AIDS Res. Hum. Retroviruses* **23**, 1083–1086 (2007).
- 479 27. Gonzalez-Hernandez, M. J. *et al.* Expression of Human Endogenous Retrovirus Type K  
480 (HML-2) Is Activated by the Tat Protein of HIV-1. *J. Virol.* **86**, 7790–7805 (2012).

- 481 28. Contreras-Galindo, R. *et al.* HIV infection reveals widespread expansion of novel  
482 centromeric human endogenous retroviruses. *Genome Res.* **23**, 1505–1513 (2013).
- 483 29. Jones, R. B. *et al.* LINE-1 retrotransposable element DNA accumulates in HIV-1-infected  
484 cells. *J. Virol.* **87**, 13307–13320 (2013).
- 485 30. Jones, R. B. *et al.* HIV-1 infection induces retrotransposition of LINE-1 elements.  
486 *Retrovirology* **6**, P43, 1742-4690-6-S2-P43 (2009).
- 487 31. O’Carroll, I. P. *et al.* Structural Mimicry Drives HIV-1 Rev-Mediated HERV-K  
488 Expression. *J. Mol. Biol.* **432**, 166711 (2020).
- 489 32. van der Kuyl, A. C. HIV infection and HERV expression: a review. *Retrovirology* **9**, 6  
490 (2012).
- 491 33. Kyriakou, E. & Magiorkinis, G. Interplay between endogenous and exogenous human  
492 retroviruses. *Trends Microbiol.* **31**, 933–946 (2023).
- 493 34. Brinzevich, D. *et al.* HIV-1 Interacts with Human Endogenous Retrovirus K (HML-2)  
494 Envelopes Derived from Human Primary Lymphocytes. *J. Virol.* **88**, 6213–6223 (2014).
- 495 35. An, D. S., Xie, Y. & Chen, I. S. Y. Envelope Gene of the Human Endogenous Retrovirus  
496 HERV-W Encodes a Functional Retrovirus Envelope. *J. Virol.* **75**, 3488–3489 (2001).
- 497 36. Ogata, T., Okui, N., Sakuma, R., Kobayashi, N. & Kitamura, Y. Integrase of human  
498 endogenous retrovirus K-10 supports the replication of replication-incompetent Int- human  
499 immunodeficiency virus type 1 mutant. *Jpn. J. Infect. Dis.* **52**, 251–252 (1999).
- 500 37. Monde, K., Contreras-Galindo, R., Kaplan, M. H., Markovitz, D. M. & Ono, A. Human  
501 Endogenous Retrovirus K Gag Coassembles with HIV-1 Gag and Reduces the Release  
502 Efficiency and Infectivity of HIV-1. *J. Virol.* **86**, 11194–11208 (2012).

- 503 38. Terry, S. N. *et al.* Expression of HERV-K108 envelope interferes with HIV-1 production.  
504 *Virology* **509**, 52–59 (2017).
- 505 39. Fueyo, R., Judd, J., Feschotte, C. & Wysocka, J. Roles of transposable elements in the  
506 regulation of mammalian transcription. *Nat. Rev. Mol. Cell Biol.* **23**, 481–497 (2022).
- 507 40. Du, A. Y., Chobirko, J. D., Zhuo, X., Feschotte, C. & Wang, T. *Regulatory Transposable*  
508 *Elements in the Encyclopedia of DNA Elements*.  
509 <http://biorxiv.org/lookup/doi/10.1101/2023.09.05.556380> (2023)  
510 doi:10.1101/2023.09.05.556380.
- 511 41. Chuong, E. B., Elde, N. C. & Feschotte, C. Regulatory evolution of innate immunity  
512 through co-option of endogenous retroviruses. *Science* **351**, 1083–1087 (2016).
- 513 42. Kassiotis, G. & Stoye, J. P. Immune responses to endogenous retroelements: taking the  
514 bad with the good. *Nat. Rev. Immunol.* **16**, 207–219 (2016).
- 515 43. Payer, L. M. & Burns, K. H. Transposable elements in human genetic disease. *Nat. Rev.*  
516 *Genet.* **20**, 760–772 (2019).
- 517 44. Küry, P. *et al.* Human Endogenous Retroviruses in Neurological Diseases. *Trends Mol.*  
518 *Med.* **24**, 379–394 (2018).
- 519 45. Jansz, N. & Faulkner, G. J. Endogenous retroviruses in the origins and treatment of  
520 cancer. *Genome Biol.* **22**, 147 (2021).
- 521 46. Dopkins, N. & Nixon, D. F. Activation of human endogenous retroviruses and its  
522 physiological consequences. *Nat. Rev. Mol. Cell Biol.* (2023) doi:10.1038/s41580-023-00674-  
523 z.
- 524 47. De Mulder, M. *et al.* Anti-HERV-K (HML-2) capsid antibody responses in HIV elite  
525 controllers. *Retrovirology* **14**, 41 (2017).

- 526 48. Dobin, A. *et al.* STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15–21  
527 (2013).
- 528 49. Bendall, M. L. *et al.* Telescope: Characterization of the retrotranscriptome by accurate  
529 estimation of transposable element expression. *PLoS Comput. Biol.* **15**, e1006453 (2019).
- 530 50. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion  
531 for RNA-seq data with DESeq2. *Genome Biol.* **15**, 550 (2014).
- 532 51. Gao, C.-H., Yu, G. & Cai, P. ggVennDiagram: An Intuitive, Easy-to-Use, and Highly  
533 Customizable R Package to Generate Venn Diagram. *Front. Genet.* **12**, 706907 (2021).
- 534 52. Ito, K. & Murphy, D. Application of ggplot2 to Pharmacometric Graphics. *CPT*  
535 *Pharmacomet. Syst. Pharmacol.* **2**, e79 (2013).
- 536 53. Dillon, S. M. *et al.* An altered intestinal mucosal microbiome in HIV-1 infection is  
537 associated with mucosal and systemic immune activation and endotoxemia. *Mucosal*  
538 *Immunol.* **7**, 983–994 (2014).
- 539 54. Dillon, S. M. *et al.* Gut dendritic cell activation links an altered colonic microbiome to  
540 mucosal and systemic T-cell activation in untreated HIV-1 infection. *Mucosal Immunol.* **9**, 24–  
541 37 (2016).
- 542 55. O’Leary, N. A. *et al.* Reference sequence (RefSeq) database at NCBI: current status,  
543 taxonomic expansion, and functional annotation. *Nucleic Acids Res.* **44**, D733–D745 (2016).
- 544 56. Harrow, J. *et al.* GENCODE: the reference human genome annotation for The ENCODE  
545 Project. *Genome Res.* **22**, 1760–1774 (2012).
- 546 57. Thorvaldsdottir, H., Robinson, J. T. & Mesirov, J. P. Integrative Genomics Viewer (IGV):  
547 high-performance genomics data visualization and exploration. *Brief. Bioinform.* **14**, 178–192  
548 (2013).



- 549 58. Pertea, M. *et al.* StringTie enables improved reconstruction of a transcriptome from  
550 RNA-seq reads. *Nat. Biotechnol.* **33**, 290–295 (2015).
- 551 59. Jones, S. T. *et al.* Altered Immunoglobulin Repertoire and Decreased IgA Somatic  
552 Hypermutation in the Gut during Chronic HIV-1 Infection. *J. Virol.* **96**, e0097622 (2022).
- 553 60. Dillon, S. M. *et al.* Granzyme B+ CD4 T cells accumulate in the colon during chronic  
554 HIV-1 infection. *Gut Microbes* **14**, 2045852 (2022).
- 555 61. Kassiotis, G. The Immunological Conundrum of Endogenous Retroelements. *Annu. Rev.*  
556 *Immunol.* **41**, annurev-immunol-101721-033341 (2023).
- 557 62. Curty, G. *et al.* Human Endogenous Retrovirus Expression Is Upregulated in the Breast  
558 Cancer Microenvironment of HIV Infected Women: A Pilot Study. *Front. Oncol.* **10**, 553983  
559 (2020).
- 560 63. Dai, L. *et al.* Transactivation of human endogenous retrovirus K (HERV-K) by KSHV  
561 promotes Kaposi's sarcoma development. *Oncogene* **37**, 4534–4545 (2018).
- 562 64. Macchietto, M. G., Langlois, R. A. & Shen, S. S. Virus-induced transposable element  
563 expression up-regulation in human and mouse host cells. *Life Sci. Alliance* **3**, e201900536  
564 (2020).
- 565 65. Vargiu, L. *et al.* Classification and characterization of human endogenous retroviruses;  
566 mosaic forms are common. *Retrovirology* **13**, 7 (2016).
- 567
- 568
- 569
- 570
- 571

572 **Figure Legends**

573

574 **Figure 1. HIV-1 status influences endogenous retroelement expression in the gut**

575 **microenvironment**

576 Heatmap demonstrating the normalized per sample abundances of EREs following the  
577 preprocessing filtering of reads in uninfected controls (red) (n = 13) vs PLWH (blue) (n = 19)  
578 individuals. ERE reads were filtered to possess at least 2 reads in 10% of the total samples for  
579 quality assurance (A). Heatmap demonstrating the normalized per sample abundances of EREs  
580 differentially expressed with an adjusted p value of  $\leq 0.05$  and a LFC  $\geq 1$  or  $\leq -1$  between  
581 uninfected controls (red) (n = 13) and PLWH (blue) (n = 19) gut biopsies. All statistics were  
582 performed in DESEQ using the Wald's Test. Adjusted p values were calculated using default  
583 parameters for a Benjamini-Hochberg correction (B). Volcano plot demonstrating the average  
584 fold change  $\geq 1$  or  $\leq -1$  and an adjusted p value of  $\leq 0.05$  and a LFC between uninfected controls (n  
585 = 13) and PLWH (n = 19) gut biopsies. All statistics were performed in DESEQ using the Wald's  
586 Test. Adjusted p values were calculated using default parameters for a Benjamini-Hochberg  
587 correction (C).

588

589 **Figure 2. Correlation between gut endogenous retroelement expression and viral load in**  
590 **people living with HIV-1**

591 Scatterplot demonstrating the viral load from serum on the X axis and normalized expression of  
592 L1FLnI\_1q23.1s in colon biopsies on the Y axis. uninfected controls (red) (n = 13) vs PLWH  
593 (blue) (n = 19) (A). Normalized expression of L1FLnI\_1q23.1s in colon biopsies from  
594 uninfected controls (red) (n = 13) vs PLWH (blue) (n = 19). Post hoc significance values

595 determined with unpaired T test (B). Normalized expression of L1FLnI\_1q23.1s in PBMCs from  
596 uninfected controls (red) (n = 13) vs PLWH (blue) (n = 19). Post hoc significance values  
597 determined with unpaired T test (C). Interferome array of L1FLnI\_1q23.1s expression following  
598 IFN-a1 (n = 3), -a2 (n = 3), -a5 (n = 3), -a8 (n = 3), -a14 (n = 3), and -b (n = 3) treated gut CD4+  
599 T cells when compared to mock (m) treatment (n=3). ANOVA performed for significance with  
600 post hoc significance values determined via unpaired T test (D). IGV representation of  
601 L1FLnI\_1q23.1s locus provided by the Telescope annotation in the Refseq and Gencode  
602 annotations. StringTie reconstructed transcriptomes demonstrate putative transcripts present in  
603 sequencing collected from the colon of uninfected controls and PLWH individuals (E).  
604 Scatterplot demonstrating the viral load from serum on the X axis and normalized expression of  
605 L1FLnI\_5q32o in colon biopsies on the Y axis. Uninfected controls (red) (n = 13) vs PLWH  
606 (blue) (n = 19) (F). Normalized expression of L1FLnI\_5q32o in colon biopsies from uninfected  
607 controls (red) (n = 13) vs PLWH (blue) (n = 19). Post hoc significance values determined with  
608 unpaired T test (G). Normalized expression of L1FLnI\_5q32o in PBMCs from uninfected  
609 controls (red) (n = 13) vs PLWH (blue) (n = 19). Post hoc significance values determined with  
610 unpaired T test (H). Interferome array of L1FLnI\_5q32o expression following IFN-a1 (n = 3), -  
611 a2 (n = 3), -a5 (n = 3), -a8 (n = 3), -a14 (n = 3), and -b (n = 3) treated gut CD4+ T cells when  
612 compared to mock (m) treatment (n=3). ANOVA performed for significance with post hoc  
613 significance values determined via unpaired T test (I). IGV representation of L1FLnI\_5q32o  
614 locus provided by the Telescope annotation in the Refseq and Gencode annotations. StringTie  
615 reconstructed transcriptomes demonstrate putative transcripts present in sequencing collected  
616 from the colon of uninfected controls and PLWH individuals (J). Scatterplot demonstrating the  
617 viral load from serum on the X axis and normalized expression of LTR19\_12p13.31 in colon

618 biopsies on the Y axis. uninfected controls (red) (n = 13) vs PLWH (blue) (n = 19) (K).  
619 Normalized expression of LTR19\_12p13.31 in colon biopsies from uninfected controls (red) (n =  
620 13) vs PLWH (blue) (n = 19). Post hoc significance values determined with unpaired T test (L).  
621 Normalized expression of LTR19\_12p13.31 in PBMCs from uninfected controls (red) (n = 13)  
622 vs PLWH (blue) (n = 19). Post hoc significance values determined with unpaired T test (M).  
623 Interferome array of L1FLnI\_1q23.1s expression following IFN- $\alpha$ 1 (n = 3), - $\alpha$ 2 (n = 3), - $\alpha$ 5 (n =  
624 3), - $\alpha$ 8 (n = 3), - $\alpha$ 14 (n = 3), and - $\beta$  (n = 3) treated gut CD4+ T cells when compared to mock (m)  
625 treatment (n=3). ANOVA performed for significance with post hoc significance values  
626 determined via unpaired T test (N). IGV representation of LTR19\_12p13.31 locus provided by  
627 the Telescope annotation in the Refseq and Gencode annotations. StringTie reconstructed  
628 transcriptomes demonstrate putative transcripts present in sequencing collected from the colon of  
629 uninfected controls and PLWH individuals (O).

630

631 **Figure 3. Correlation Between LTR19\_12p13.31 and L1FLnI\_1q23.1s expression and**  
632 **immune signatures of the gut microenvironment in people living with HIV-1.**

633 For all samples uninfected controls (red) (n = 13) vs PLWH (blue) (n = 19). Scatterplot  
634 demonstrating the CD4+ T Cells per gram on the X axis and normalized expression of  
635 LTR19\_12p13.31 in colon biopsies on the Y axis (A). Scatterplot demonstrating the CD4+ T  
636 Cells per gram on the X axis and normalized expression of L1FLnI\_1q23.1s in colon biopsies on  
637 the Y axis (B). Scatterplot demonstrating the CD8+ T Cells per gram on the X axis and  
638 normalized expression of LTR19\_12p13.31 in colon biopsies on the Y axis (C). Scatterplot  
639 demonstrating the CD8+ T Cells per gram on the X axis and normalized expression of  
640 L1FLnI\_1q23.1s in colon biopsies on the Y axis (D). Scatterplot demonstrating the IFN $\gamma$ +CD8+

641 T Cells per gram on the X axis and normalized expression of LTR19\_12p13.31 in colon biopsies  
642 on the Y axis (E). Scatterplot demonstrating the IFN $\gamma$ +CD8 $^+$  T Cells per gram on the X axis and  
643 normalized expression of L1FLnI\_1q23.1s in colon biopsies on the Y axis (F). Scatterplot  
644 demonstrating the CD11c $^+$  mDCs per gram on the X axis and normalized expression of  
645 LTR19\_12p13.31 in colon biopsies on the Y axis (G). Scatterplot demonstrating the CD11c $^+$   
646 mDCs per gram on the X axis and normalized expression of L1FLnI\_1q23.1s in colon biopsies  
647 on the Y axis (H). Scatterplot demonstrating the pDCs per gram on the X axis and normalized  
648 expression of LTR19\_12p13.31 in colon biopsies on the Y axis (I). Scatterplot demonstrating the  
649 pDCs per gram on the X axis and normalized expression of L1FLnI\_1q23.1s in colon biopsies on  
650 the Y axis (J). Scatterplot demonstrating the CD1c $^-$  mDCs per gram on the X axis and  
651 normalized expression of LTR19\_12p13.31 in colon biopsies on the Y axis (K). Scatterplot  
652 demonstrating the CD1c $^-$  mDCs per gram on the X axis and normalized expression of  
653 L1FLnI\_1q23.1s in colon biopsies on the Y axis (L).

654

655

656

657

658

659

660

661

662

663

664 **Supplemental Legends**

665

666 **Figure S1: Characterization of ERE expression profiles in the colonic microenvironment of**

667 **PLWH.** Principal component analysis (PCA) plot based solely on endogenous retroelement

668 (ERE) abundances demonstrate variance in sample distribution between uninfected controls (red)

669 (n = 13) and PLWH (blue) (n = 19) gut biopsies (A). Stacked bar charts demonstrating mean

670 abundance of exonic, intronic, and intergenic EREs as the average proportion of ERE denoted

671 reads from gut biopsies collected from uninfected controls (n = 13) and PLWH (n = 19)

672 individuals (B). Stacked bar charts demonstrating mean abundance of LINE1 and HERV

673 elements as the average proportion of ERE denoted reads from gut biopsies collected from

674 uninfected controls (n = 13) and PLWH (n = 19) individuals (C). Stacked bar charts

675 demonstrating the proportional abundance of chromosomes of origin for ERE loci from gut

676 biopsies collected from uninfected controls (n = 13) and PLWH (n = 19) individuals (D). Stacked

677 bar charts demonstrating category of EREs the average proportion of TE denoted reads from gut

678 biopsies collected from uninfected controls (n = 13) and PLWH (n = 19) individuals (E). Stacked

679 bar charts demonstrating mean abundance of transposable element (TE) families as the average

680 proportion of ERE denoted reads from gut biopsies collected from uninfected controls (n = 13)

681 and PLWH (n = 19) individuals (F).

682

683 **Figure S2: Characterization of ERE expression profiles in uninfected gut CD4+ T cells**

684 **activated with IFN-Is.** PCA plot based solely on ERE abundances demonstrate variance in

685 sample distribution between mock (m) (n=3), IFN $\alpha$ 1 (a1) (n = 3), IFN $\alpha$ 2 (a2) (n = 3), IFN $\alpha$ 5 (a5)

686 (n = 3), IFN $\alpha$ 8 (a8) (n = 3), IFN $\alpha$ 14 (a14) (n = 3), and IFN $\beta$  (b) (n =3) treated gut CD4+ T cells

687 (A). Stacked bar charts demonstrating mean abundance of exonic, intronic, and intergenic TEs as  
688 the average proportion of ERE denoted reads from m (n=3), a1 (n = 3), a2 (n = 3), a5 (n = 3), a8  
689 (n = 3), a14 (n = 3), and b (n =3) treated gut CD4+ T cells (B). Stacked bar charts demonstrating  
690 mean abundance of LINE1 and HERV elements as the average proportion of ERE denoted reads  
691 from m (n=3), a1 (n = 3), a2 (n = 3), a5 (n = 3), a8 (n = 3), a14 (n = 3), and b (n =3) treated gut  
692 CD4+ T cells (C). Stacked bar charts demonstrating the chromosomal location of ERE denoted  
693 reads from m (n=3), a1 (n = 3), a2 (n = 3), a5 (n = 3), a8 (n = 3), a14 (n = 3), and b (n =3) treated  
694 gut CD4+ T cells (D). Stacked bar charts demonstrating ERE category as the average proportion  
695 of TE denoted reads from m (n=3), a1 (n = 3), a2 (n = 3), a5 (n = 3), a8 (n = 3), a14 (n = 3), and  
696 b (n =3) treated gut CD4+ T cells (E). Stacked bar charts demonstrating mean abundance of TE  
697 families as the average proportion of TE denoted reads from m (n=3), a1 (n = 3), a2 (n = 3), a5 (n  
698 = 3), a8 (n = 3), a14 (n = 3), and b (n =3) treated gut CD4+ T cells (F).

699

700 **Figure S3: IFN-Is induce the differential expression of EREs in gut CD4+ T cells.** Heatmap  
701 demonstrating the normalized per sample abundances of TEs following the preprocessing  
702 filtering of reads in m (gold) (n=3), a1 (purple) (n = 3), a2 (pink) (n = 3), a5 (green) (n = 3), a8  
703 (blue) (n = 3), a14 (red) (n = 3), and b (teal) (n =3) treated gut CD4+ T Cells. ERE reads were  
704 filtered to possess at least 2 reads in 10% of the total samples for quality assurance (A).  
705 Heatmap demonstrating the normalized per sample abundances of EREs differentially expressed  
706 with an adjusted p value of  $\leq 0.05$  and a LFC  $\geq 1$  or  $\leq -1$  between m (red) (n=3) and a1 (blue)  
707 (n=3) treated gut CD4+ T cells. All statistics were performed in DESEQ using the Wald's Test.  
708 Adjusted p values were calculated using default parameters for a Benjamini-Hochberg correction  
709 (B). Heatmap demonstrating the normalized per sample abundances of EREs differentially

710 expressed with an adjusted p value of  $\leq 0.05$  and a  $LFC \geq 1$  or  $\leq -1$  between m (red) (n=3) and a2  
711 (blue) (n=3) treated gut CD4+ T cells. All statistics were performed in DESEQ using the Wald's  
712 Test. Adjusted p values were calculated using default parameters for a Benjamini-Hochberg  
713 correction (C). Heatmap demonstrating the normalized per sample abundances of EREs  
714 differentially expressed with an adjusted p value of  $\leq 0.05$  and a  $LFC \geq 1$  or  $\leq -1$  between m (red)  
715 (n=3) and a5 (blue) (n=3) treated gut CD4+ T cells. All statistics were performed in DESEQ  
716 using the Wald's Test. Adjusted p values were calculated using default parameters for a  
717 Benjamini-Hochberg correction (D). Heatmap demonstrating the normalized per sample  
718 abundances of EREs differentially expressed with an adjusted p value of  $\leq 0.05$  and a  $LFC \geq 1$   
719 or  $\leq -1$  between m (red) (n=3) and a8 (blue) (n=3) treated gut CD4+ T cells. All statistics were  
720 performed in DESEQ using the Wald's Test. Adjusted p values were calculated using default  
721 parameters for a Benjamini-Hochberg correction (E). Heatmap demonstrating the normalized per  
722 sample abundances of EREs differentially expressed with an adjusted p value of  $\leq 0.05$  and a  
723  $LFC \geq 1$  or  $\leq -1$  between m (red) (n=3) and a14 (blue) (n=3) treated gut CD4+ T cells. All  
724 statistics were performed in DESEQ using the Wald's Test. Adjusted p values were calculated  
725 using default parameters for a Benjamini-Hochberg correction (F). Heatmap demonstrating the  
726 normalized per sample abundances of EREs differentially expressed with an adjusted p value of  
727  $\leq 0.05$  and a  $LFC \geq 1$  or  $\leq -1$  between m (red) (n=3) and b (blue) (n=3) treated gut CD4+ T cells.  
728 All statistics were performed in DESEQ using the Wald's Test. Adjusted p values were calculated  
729 using default parameters for a Benjamini-Hochberg correction (G). Venn diagram of shared vs  
730 uniquely downregulated ERE loci across a1 (n = 3), a2 (n = 3), a5 (n = 3), a8 (n = 3), a14 (n = 3),  
731 and b (n = 3) treated gut CD4+ T cells when compared to m (H). Venn diagram of shared vs



732 uniquely upregulated ERE loci across a1 (n = 3), a2 (n = 3), a5 (n = 3), a8 (n = 3), a14 (n = 3),  
733 and b (n = 3) treated gut CD4+ T cells when compared to m (I).

734

735 **Figure S4: Upregulation of ERE loci in gut CD4+ T cells activated with IFN-Is.** Volcano plot

736 demonstrating the average fold change  $\geq 1$  or  $\leq -1$  and an adjusted p value of  $\leq 0.05$  and a LFC

737 between m (n = 3) and a1 (n = 3) treated gut CD4+ T cells. All statistics were performed in

738 DESEQ using the Wald's Test. Adjusted p values were calculated using default parameters for a

739 Benjamini-Hochberg correction (A). Volcano plot demonstrating the average fold change  $\geq 1$  or  $\leq -$

740 1 and an adjusted p value of  $\leq 0.05$  and a LFC between m (n = 3) and a2 (n = 3) treated gut CD4+

741 T cells. All statistics were performed in DESEQ using the Wald's Test. Adjusted p values were

742 calculated using default parameters for a Benjamini-Hochberg correction (B). Volcano plot

743 demonstrating the average fold change  $\geq 1$  or  $\leq -1$  and an adjusted p value of  $\leq 0.05$  and a LFC

744 between m (n = 3) and a5 (n = 3) treated gut CD4+ T cells. All statistics were performed in

745 DESEQ using the Wald's Test. Adjusted p values were calculated using default parameters for a

746 Benjamini-Hochberg correction (C). Volcano plot demonstrating the average fold change  $\geq 1$  or  $\leq -$

747 1 and an adjusted p value of  $\leq 0.05$  and a LFC between m (n = 3) and a8 (n = 3) treated gut CD4+

748 T cells. All statistics were performed in DESEQ using the Wald's Test. Adjusted p values were

749 calculated using default parameters for a Benjamini-Hochberg correction (D). Volcano plot

750 demonstrating the average fold change  $\geq 1$  or  $\leq -1$  and an adjusted p value of  $\leq 0.05$  and a LFC

751 between m (n = 3) and a14 (n = 3) treated gut CD4+ T cells. All statistics were performed in

752 DESEQ using the Wald's Test. Adjusted p values were calculated using default parameters for a

753 Benjamini-Hochberg correction (E). Volcano plot demonstrating the average fold change  $\geq 1$  or  $\leq -$

754 1 and an adjusted p value of  $\leq 0.05$  and a LFC between m (n = 3) and b (n = 3) treated gut CD4+

755 T cells. All statistics were performed in DESEQ using the Wald's Test. Adjusted p values were  
756 calculated using default parameters for a Benjamini-Hochberg correction (F).

757

758 **Figure S5: HIV-1 status and IFN-Is induce 7 shared EREs in the gut microenvironment.**

759 Venn diagram of shared vs uniquely downregulated TE loci across PLWH (n = 19) vs uninfected  
760 controls (n = 13) gut biopsies, and a1 (n = 3), a2 (n = 3), a5 (n = 3), a8 (n = 3), a14 (n = 3), and b  
761 (n = 3) treated gut CD4+ T cells when compared to m (A). Venn diagram of shared vs uniquely  
762 upregulated TE loci across PLWH (n = 19) vs uninfected controls (n = 13) gut biopsies, and a1 (n  
763 = 3), a2 (n = 3), a5 (n = 3), a8 (n = 3), a14 (n = 3), and b (n = 3) treated gut CD4+ T cells when  
764 compared to m (B). Gut biopsies from uninfected controls (n = 13) and PLWH (n = 19)  
765 individuals (left) as well interferome assay responses to type 1 interferons (n = 3) (right) show  
766 significant upregulation in HARLEQUIN\_17q12 (C), HERV4\_4q22.1 (D), MER101\_2p25.2 (E),  
767 MER4\_7q21.2 (F), L1FLnI\_1p22.21 (G), L1FLnI\_9p21.1ha (H), and L1FLnI\_17q12k (I). All  
768 statistics were performed in DESEQ using the Wald's Test. Adjusted p values were calculated  
769 using default parameters for a Benjamini-Hochberg correction. Tukey box and whisker plots for  
770 with the line demonstrating the median of expression while the large dot represents the mean.

771

772 **Figure S6: EREs of interest in the gut microenvironment show no association with CD1c+**

773 **mDC abundances.** Gut expression of L1FLnI\_1q23.1s (A), L1FLnI\_5q32o (B), and  
774 LTR19\_12p13.31 (C) show no association with CD1c+ mDC abundances in the gut  
775 microenvironment.

776

777 **Figure S7: L1FLnI\_5q32o is not associated with major cellular parameters of immune**  
778 **deregulation in PLWH.** Scatterplot demonstrating the CD4+ T Cells per gram on the X axis and  
779 normalized expression of L1FLnI\_5q32o in colon biopsies on the Y axis (A). Scatterplot  
780 demonstrating the CD8+ T Cells per gram on the X axis and normalized expression of  
781 L1FLnI\_5q32o in colon biopsies on the Y axis (B). Scatterplot demonstrating the IFN $\gamma$ +CD8+ T  
782 Cells per gram on the X axis and normalized expression of L1FLnI\_5q32o in colon biopsies on  
783 the Y axis (C). Scatterplot demonstrating the CD11c+ mDCs per gram on the X axis and  
784 normalized expression of L1FLnI\_5q32o in colon biopsies on the Y axis (D). Scatterplot  
785 demonstrating the pDCs per gram on the X axis and normalized expression of L1FLnI\_5q32o in  
786 colon biopsies on the Y axis (E). Scatterplot demonstrating the CD1c- mDCs per gram on the X  
787 axis and normalized expression of L1FLnI\_5q32o in colon biopsies on the Y axis (F).

788  
789 **Figure S8: Association between colonic L1FLnI\_1q23.1s expression and CD4+ T Cell**  
790 **subsets.** Scatterplot demonstrating the IFN $\gamma$ -IL17+CD4+ T cells per gram on the X axis and  
791 normalized expression of L1FLnI\_1q23.1s in colon biopsies on the Y axis (A). Scatterplot  
792 demonstrating the IFN $\gamma$ +IL17-CD4+ T cells per gram on the X axis and normalized expression  
793 of L1FLnI\_1q23.1s in colon biopsies on the Y axis (B). Scatterplot demonstrating the  
794 IFN $\gamma$ +IL17+CD4+ T cells per gram on the X axis and normalized expression of L1FLnI\_1q23.1s  
795 in colon biopsies on the Y axis (C). Scatterplot demonstrating the IL22+IFN $\gamma$ -IL17-CD4+ T cells  
796 per gram on the X axis and normalized expression of L1FLnI\_1q23.1s in colon biopsies on the Y  
797 axis (D).

798

799 **Figure S9: Association between colonic L1FLnI\_5q32o expression and CD4+ T Cell subsets.**

800 Scatterplot demonstrating the IFNy-IL17+CD4+ T cells per gram on the X axis and normalized  
801 expression of L1FLnI\_5q32o in colon biopsies on the Y axis (A). Scatterplot demonstrating the  
802 IFNy+IL17-CD4+ T cells per gram on the X axis and normalized expression of L1FLnI\_5q32o  
803 in colon biopsies on the Y axis (B). Scatterplot demonstrating the IFNy+IL17+CD4+ T cells per  
804 gram on the X axis and normalized expression of L1FLnI\_5q32o in colon biopsies on the Y axis  
805 (C). Scatterplot demonstrating the IL22+IFNy-IL17-CD4+ T cells per gram on the X axis and  
806 normalized expression of L1FLnI\_5q32o 1s in colon biopsies on the Y axis (D).

807

808 **Figure S10: Association between colonic LTR19\_12p13.31 expression and CD4+ T Cell**

809 **subsets.** Scatterplot demonstrating the IFNy-IL17+CD4+ T cells per gram on the X axis and  
810 normalized expression of LTR19\_12p13.31 in colon biopsies on the Y axis (A). Scatterplot  
811 demonstrating the IFNy+IL17-CD4+ T cells per gram on the X axis and normalized expression  
812 of LTR19\_12p13.31 in colon biopsies on the Y axis (B). Scatterplot demonstrating the  
813 IFNy+IL17+CD4+ T cells per gram on the X axis and normalized expression of  
814 LTR19\_12p13.31 in colon biopsies on the Y axis (C). Scatterplot demonstrating the IL22+IFNy-  
815 IL17-CD4+ T cells per gram on the X axis and normalized expression of LTR19\_12p13.31 in  
816 colon biopsies on the Y axis (D).

817

818 **Figure S11: Colonic expression of EREs of interest produce negligible correlations with**

819 **serum IL-6 and LPS.** Scatterplots demonstrating serum lipopolysaccharide (LPS)  
820 concentrations on the X axis and normalized expression of L1FLnI\_1q23.1s (A), L1FLnI\_5q32o  
821 (B), LTR19\_12p13.31 (C) in colon biopsies on the Y axis. Scatterplots demonstrating serum IL-6

822 concentrations on the X axis and normalized expression of L1FLnI\_1q23.1s (D), L1FLnI\_5q32o  
823 (E), LTR19\_12p13.31 (F) in colon biopsies on the Y axis.

824

825 **Figure S12: HIV-1 status influences endogenous retroelement expression in the PBMC**

826 **fraction.** Heatmap demonstrating the normalized per sample abundances of EREs following the

827 preprocessing filtering of reads in uninfected controls (red) (n = 13) vs PLWH (blue) (n = 19)

828 individuals. ERE reads were filtered to possess at least 2 reads in 10% of the total samples for

829 quality assurance (A). Heatmap demonstrating the normalized per sample abundances of EREs

830 differentially expressed with an adjusted p value of  $\leq 0.05$  and a LFC  $\geq 1$  or  $\leq -1$  between

831 uninfected controls (red) (n = 13) and PLWH (blue) (n = 19) gut biopsies. All statistics were

832 performed in DESEQ using the Wald's Test. Adjusted p values were calculated using default

833 parameters for a Benjamini-Hochberg correction (B). PCA plot based solely on ERE abundances

834 demonstrate no variance in sample distribution between uninfected controls (red) (n = 13) and

835 PLWH (blue) (n = 19) PBMCs (C).

836

837

838

839

840

841

842

843

844

845 **Supplemental Table**

846

|  | Controls       | PLWH           | P value |
|--|----------------|----------------|---------|
| Number of study participants                       | 13             | 19             |         |
| Age  |                |                |         |
| <i>Median (min, max) (years)</i>                   | 33 (23, 54)    | 33 (22, 58)    | 0.96    |
| Sex  |                |                |         |
| <i>Male</i>  | 8              | 13             | 0.72    |
| <i>Female</i>                                      | 5              | 6              |         |
| Ethnicity  |                |                |         |
| <i>Non-Hispanic</i>                                | 11             | 14             | 0.67    |
| <i>Hispanic</i>                                    | 2              | 5              |         |
| Race   |                |                |         |
| <i>White/Caucasian</i>                             | 9              | 15             | 0.62    |
| <i>Black/African American</i>                      | 2              | 3              |         |
| <i>Asian</i>                                       | 2              | 1              |         |
| Men who have sex with men (MSM)                    |                |                |         |
| <i>Yes</i>   | 1              | 12             | 0.003   |
| <i>No</i>  | 12             | 7              |         |
| Reported intravenous drug use (IDU)*               |                |                |         |
| <i>Yes</i>   | 0              | 4              | 0.11    |
| <i>No</i>  | 14             | 14             |         |
| Blood CD4 count                                    |                |                |         |
| <i>Median (min, max) (cells/<math>\mu</math>l)</i> | 720 (468,1071) | 429 (221, 836) | 0.002   |
| Plasma HIV RNA copies/ml                           |                |                |         |

|                          |     |                      |
|--------------------------|-----|----------------------|
| <i>Median (min, max)</i> | N/A | 26000 (2880, 196000) |
|--------------------------|-----|----------------------|

Years since first HIV-1 seropositive test

|                          |     |                  |
|--------------------------|-----|------------------|
| <i>Median (min, max)</i> | N/A | 3.5 (0.17, 15.0) |
|--------------------------|-----|------------------|

---

847 Study participants were selected from a completed clinical study<sup>53</sup>. Values are shown as median  
848 (range) for continuous measures and numbers for categorical measures. Statistical analyses were  
849 performed using Mann-Whitney test for continuous characteristics and Fishers exact test to  
850 compare categorical characteristics between control and PWH groups. \*not reported for one  
851 person in PWH cohort. N/A: not applicable.

852

853

854

855

856

857

858

859

860

861

862

863

864

865

866

867

868 **Research in Context**

869

870 *Evidence before this study*

871

872 Previous studies have demonstrated that HIV-1 infection alters the physiology of the GI tissues,  
873 where it forms quiescent reservoirs. In chronic HIV-1, the sustainment of antiviral immune  
874 responses through poorly understood mechanisms likely contributes to pathogenesis and  
875 prohibits effective clearance of the viral reservoirs. EREs comprise a substantial portion of the  
876 human genome that has been implicated in HIV-1 pathogenesis but remains understudied in  
877 comparison to coding genes. Therefore, studying the activity of EREs in tissues such as the GI  
878 tract may help further define the physiology of immunopathologies that contribute to HIV-1  
879 reservoir persistence.

880

881 *Added value of this study*

882

883 Colon pinch biopsies from PLWH demonstrate differential expression of 59 EREs when  
884 compared to uninfected controls. Of these 59, 3 possess near-significant correlations with viral  
885 load. Further analysis into cellular composition of the gut microenvironment demonstrates that 2  
886 the EREs LTR19\_12p13.31 and L1FLnI\_1q23.1s possess significant associations with immune  
887 cell phenotypes indicative of localized HIV-1 pathogenesis. Therefore, high expression of  
888 LTR19\_12p13.31 and L1FLnI\_1q23.1s can function as markers of GI HIV-1 reservoirs, as well  
889 as potentially possess undefined roles in human health.

890



891 *Implications of all the available evidence*

892

893 Recurrent observations suggest pathophysiological roles for differentially expressed EREs in

894 diseased tissues. In HIV-1 infection, EREs can be over expressed due to trans-activation of

895 HERV LTRs and shifts in the regulome that permit the expression of typically silent elements.

896 However, it has not been established how EREs may be deregulated in the gut where


897 immunopathologies persist surrounding viral reservoirs. Correlations between ERE expression

898 and cellular composition demonstrate that certain EREs may be indicative of cell type


899 abundances thought to drive GI-specific immunopathologies resultant from HIV-1 infection.

# Controls vs PLWH Gut Biopsies

**A**



**B**



**C**

